Cargando…

EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE

PURPOSE: To evaluate intravitreal aflibercept in macular telangiectasia Type 1 (MacTel 1) patients and measure their ocular angiogenic profile. METHODS: Eight subjects with MacTel 1 refractory to bevacizumab, ranibizumab, or laser therapy and switched to aflibercept were included. Best-corrected vis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kowalczuk, Laura, Matet, Alexandre, Dirani, Ali, Daruich, Alejandra, Ambresin, Aude, Mantel, Irmela, Spaide, Richard F., Turck, Natacha, Behar-Cohen, Francine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Retina 2017
Materias:	Original Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732636/ https://www.ncbi.nlm.nih.gov/pubmed/28002269 http://dx.doi.org/10.1097/IAE.0000000000001424

Ejemplares similares

Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept
por: Parvin, Parmis, et al.
Publicado: (2017)

ACUTE CENTRAL SEROUS CHORIORETINOPATHY: Factors Influencing Episode Duration
por: Daruich, Alejandra, et al.
Publicado: (2017)

Proteome and Metabolome of Subretinal Fluid in Central Serous Chorioretinopathy and Rhegmatogenous Retinal Detachment: A Pilot Case Study
por: Kowalczuk, Laura, et al.
Publicado: (2018)

Resolution of foveal detachment in dome-shaped macula after treatment by spironolactone: report of two cases and mini-review of the literature
por: Dirani, Ali, et al.
Publicado: (2014)

Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance
por: Dirani, Ali, et al.
Publicado: (2018)

High Levels of C-Reactive Protein with Low Levels of Pentraxin 3 as Biomarkers for Central Serous Chorioretinopathy
por: Bousquet, Elodie, et al.
Publicado: (2023)

Oral Mineralocorticoid-Receptor Antagonists: Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy
por: Daruich, Alejandra, et al.
Publicado: (2016)

MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR–TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen
por: Mantel, Irmela, et al.
Publicado: (2019)

Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
por: Mantel, Irmela, et al.
Publicado: (2014)

Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)

Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration
por: Mantel, Irmela, et al.
Publicado: (2019)

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab
por: Shibeeb, O'Sam, et al.
Publicado: (2014)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

Posterior scleritis after biweekly aflibercept intravitreal injections
por: Hébert, Mélanie, et al.
Publicado: (2022)

Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
por: Klein, Kendra A., et al.
Publicado: (2017)

Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
por: Tatsumi, Tomoaki, et al.
Publicado: (2022)

Macular dystrophy associated with the mitochondrial DNA A3243G mutation: pericentral pigment deposits or atrophy? Report of two cases and review of the literature
por: Daruich, Alejandra, et al.
Publicado: (2014)

Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia
por: Aydoğan, Tuğba, et al.
Publicado: (2016)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
por: Ali Said, Yasmin, et al.
Publicado: (2022)

Full thickness macular hole case after intravitreal aflibercept treatment
por: Oshima, Yuji, et al.
Publicado: (2015)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose, Remya, et al.
Publicado: (2016)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

Intravitreal aflibercept for treatment of macular oedema associated with immune recovery uveitis
por: Rothova, Aniki, et al.
Publicado: (2020)

Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema
por: Lin, Tai-Chi, et al.
Publicado: (2021)

Changes in metamorphopsia following intravitreal aflibercept injection for diabetic macular edema
por: Murakami, Tomoya, et al.
Publicado: (2022)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
por: Nowosielska, Agnieszka
Publicado: (2019)

Intravitreal Bevacizumab for Choroidal Neovascular Membrane in Macular Telangiectasia Type 2
por: Gonzalez Martinez, Orlando G, et al.
Publicado: (2023)

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015)

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
por: Herbaut, Antoine, et al.
Publicado: (2017)

Levels of the oxidative stress biomarker malondialdehyde in tears of patients with central serous chorioretinopathy relate to disease activity
por: Daruich, Alejandra, et al.
Publicado: (2020)

Iron is neurotoxic in retinal detachment and transferrin confers neuroprotection
por: Daruich, Alejandra, et al.
Publicado: (2019)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study
por: Rowe, Lucas W., et al.
Publicado: (2023)

Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration
por: Ferrone, Philip J, et al.
Publicado: (2014)

Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Chhablani, Jay
Publicado: (2015)

The Efficacy of Intravitreal Aflibercept in Submacular Hemorrhage Secondary to Wet Age-related Macular Degeneration
por: Shin, Kyung-Hoon, et al.
Publicado: (2016)

Effects of Intravitreal Aflibercept on Retinal Function and Improvement of Macular Edema Associated With Diabetic Retinopathy
por: Ichio, Atsushi, et al.
Publicado: (2020)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
por: Tran, Thi Ha Chau, et al.
Publicado: (2021)

Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept
por: Yildiz, Dilan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vtpad43krldlja28u7ecm9kmbs